Moleculin Biotech To Effect 1-for-20 Reverse Stock Split
(RTTNews) - On Friday, Moleculin Biotech, Inc. (MBRX) announced that it plans to effect a 1-for-20 reverse stock split of its common stock, effective October 20.
The company's common stock will begin trading on the Nasdaq Capital Market on October 20, 2026, on a split-adjusted basis under the existing ticker MBRX.
The company will implement a 1-for-20 reverse stock split on October 20, 2026, reducing outstanding shares from approximately 20.9 million to 1.05 million. Fractional shares will be paid in cash, while the $0.001 par value and 500 million authorized shares will remain unchanged.
On the Nasdaq, the shares were trading 17.37 percent down at $0.3058.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.